AVEO Pharmaceuticals (AVEO) Receives New Coverage from Analysts at National Securities

National Securities assumed coverage on shares of AVEO Pharmaceuticals (NASDAQ:AVEO) in a report released on Thursday, March 28th, The Fly reports. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Several other research firms have also recently commented on AVEO. HC Wainwright cut AVEO Pharmaceuticals from a buy rating to a neutral rating and set a $1.00 price target for the company. in a report on Friday, February 1st. ValuEngine cut AVEO Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, January 31st. BidaskClub raised AVEO Pharmaceuticals from a sell rating to a hold rating in a report on Tuesday, January 15th. Robert W. Baird assumed coverage on AVEO Pharmaceuticals in a report on Thursday, January 3rd. They issued an outperform rating and a $3.00 price target for the company. Finally, FBR & Co set a $3.00 price target on AVEO Pharmaceuticals and gave the company a buy rating in a report on Thursday, December 20th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. AVEO Pharmaceuticals presently has an average rating of Hold and a consensus target price of $1.96.

Shares of NASDAQ AVEO traded down $0.09 during trading hours on Thursday, hitting $1.01. 4,369,636 shares of the company’s stock were exchanged, compared to its average volume of 16,236,170. AVEO Pharmaceuticals has a 1-year low of $0.49 and a 1-year high of $3.59. The stock has a market capitalization of $140.39 million, a PE ratio of -5.32 and a beta of 1.19.

AVEO Pharmaceuticals (NASDAQ:AVEO) last posted its quarterly earnings data on Thursday, March 14th. The biopharmaceutical company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.06) by $0.03. The business had revenue of $1.48 million for the quarter, compared to analyst estimates of $2.48 million. As a group, sell-side analysts predict that AVEO Pharmaceuticals will post -0.16 earnings per share for the current fiscal year.

In other news, major shareholder Equity Opportunities Fu Growth purchased 4,347,827 shares of the business’s stock in a transaction on Monday, April 8th. The stock was purchased at an average price of $1.14 per share, with a total value of $4,956,522.78. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 4.40% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. NEA Management Company LLC grew its stake in shares of AVEO Pharmaceuticals by 11.8% in the 4th quarter. NEA Management Company LLC now owns 20,896,038 shares of the biopharmaceutical company’s stock valued at $33,434,000 after purchasing an additional 2,198,000 shares during the period. BlackRock Inc. grew its stake in shares of AVEO Pharmaceuticals by 3.3% in the 4th quarter. BlackRock Inc. now owns 7,357,716 shares of the biopharmaceutical company’s stock valued at $11,773,000 after purchasing an additional 236,822 shares during the period. Vanguard Group Inc grew its stake in shares of AVEO Pharmaceuticals by 1.5% in the 3rd quarter. Vanguard Group Inc now owns 5,066,360 shares of the biopharmaceutical company’s stock valued at $16,770,000 after purchasing an additional 73,519 shares during the period. Vanguard Group Inc. grew its stake in shares of AVEO Pharmaceuticals by 1.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,066,360 shares of the biopharmaceutical company’s stock valued at $16,770,000 after purchasing an additional 73,519 shares during the period. Finally, Geode Capital Management LLC grew its stake in shares of AVEO Pharmaceuticals by 36.3% in the 4th quarter. Geode Capital Management LLC now owns 1,394,576 shares of the biopharmaceutical company’s stock valued at $2,231,000 after purchasing an additional 371,327 shares during the period. Institutional investors own 35.72% of the company’s stock.

AVEO Pharmaceuticals Company Profile

AVEO Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes a portfolio of targeted medicines for oncology and other areas of unmet medical need. It markets its lead candidate, tivozanib, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC).

Featured Story: What is the Rule of 72?

The Fly

Analyst Recommendations for AVEO Pharmaceuticals (NASDAQ:AVEO)

Receive News & Ratings for AVEO Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.